Literature DB >> 18714982

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.

Robert L Hudkins1, James L Diebold, Ming Tao, Kurt A Josef, Chung Ho Park, Thelma S Angeles, Lisa D Aimone, Jean Husten, Mark A Ator, Sheryl L Meyer, Beverly P Holskin, John T Durkin, Alexander A Fedorov, Elena V Fedorov, Steven C Almo, Joanne R Mathiasen, Donna Bozyczko-Coyne, Michael S Saporito, Richard W Scott, John P Mallamo.   

Abstract

The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R(2) and R(12) positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714982     DOI: 10.1021/jm8005838

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

2.  The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.

Authors:  Elizabeth M Kline; Laura M Butkovich; Joshua M Bradner; Jianjun Chang; Harris Gelbard; Val Goodfellow; W Michael Caudle; Malú G Tansey
Journal:  Exp Neurol       Date:  2019-05-08       Impact factor: 5.330

Review 3.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

4.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

5.  Lysine 63-linked ubiquitination modulates mixed lineage kinase-3 interaction with JIP1 scaffold protein in cytokine-induced pancreatic β cell death.

Authors:  Rohan K Humphrey; Shu Mei A Yu; Aditi Bellary; Sumati Gonuguntla; Myra Yebra; Ulupi S Jhala
Journal:  J Biol Chem       Date:  2012-11-21       Impact factor: 5.157

Review 6.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

Review 7.  Cellular processes associated with LRRK2 function and dysfunction.

Authors:  Rebecca Wallings; Claudia Manzoni; Rina Bandopadhyay
Journal:  FEBS J       Date:  2015-05-09       Impact factor: 5.542

8.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.

Authors:  Sérgia Velho; Carla Oliveira; Joana Paredes; Sónia Sousa; Marina Leite; Paulo Matos; Fernanda Milanezi; Ana Sofia Ribeiro; Nuno Mendes; Danilo Licastro; Auli Karhu; Maria José Oliveira; Marjolijn Ligtenberg; Richard Hamelin; Fátima Carneiro; Annika Lindblom; Paivi Peltomaki; Sérgio Castedo; Simó Schwartz; Peter Jordan; Lauri A Aaltonen; Robert M W Hofstra; Gianpaolo Suriano; Elia Stupka; Arsenio M Fialho; Raquel Seruca
Journal:  Hum Mol Genet       Date:  2009-12-02       Impact factor: 6.150

9.  Chemical IN04 Inhibits the Kinase Domain not the ROC Domain of LRRK1: Results from Homology Modeling and Molecular Docking.

Authors:  Zhenhang Chen; Weirong Xing; Li Fan
Journal:  Med Chem       Date:  2021       Impact factor: 2.745

10.  In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.

Authors:  Renée Vancraenenbroeck; Joren De Raeymaecker; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Arnout Voet; Veerle Baekelandt; Jean-Marc Taymans
Journal:  Front Mol Neurosci       Date:  2014-06-03       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.